On September 13, President Trump signed an executive order (EO) aiming to address high prescription drug prices by tying payments for certain Medicare drugs to the costs the treatments sell for outside the United States (U.S.). According to the EO, prices for provider-administered drugs would be linked to a "most-favored-nation price" drawn from the lowest price among countries that have a similar per-capita gross domestic product.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO), the American Society of Clinical Oncology (ASCO) argues that while progress has been made in raising awareness of disparities and driving research, the cancer community needs to take bolder, more aggressive steps to achieve equity for all patients.
Today President Trump signed four executive orders (EOs) aimed at addressing the high cost of prescription drugs. The EOs, as described by the White House, would: (1) address the price of insulin by requiring federally qualified health centers to pass along any available discounts to patients, (2) allow for importation of certain drugs from other countries, (3) pass manufacturer discounts on Part D drugs to patients at the pharmacy, bypassing pharmacy benefit managers, and finally (4) implement a “favored nations” policy to allow Medicare to purchase Part B drugs at the lower prices paid by foreign countries. The fourth EO will go into effect in 30 days unless drug companies lower their prices first.
On June 23, 2020, JCO: Oncology Practice published an article on rural cancer care as part of the State of Cancer Care in America series. "Closing the Rural Cancer Care Gap: Three Institutional Approaches," draws from the second event in the State of Cancer Care in America series and supporting literature to summarize the challenges to delivering high-quality care in rural communities, highlight institutional approaches to addressing these challenges, and update ASCO’s rural workforce data.
A new infographic in the May 2020 print and online issues of JCO Oncology Practice (JCO OP) outlines paths to implementing the American Society of Clinical Oncology’s (ASCO) Patient-Centered Oncology Payment (PCOP) model—an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality care. Along with the infographic, the latest issue of JCO OP features an in-depth overview of recent changes to PCOP and two invited commentaries on the model.
On May 7, 2020, the Centers for Medicare & Medicaid Services (CMS) released the Patient Protection and Affordable Care Act 2021 Notice of Benefit and Payment Parameters final rule, which updates the regulatory and financial standards for Affordable Care Act (ACA) Exchanges. The rule finalized a policy that gives insurers the discretion to not count any form of direct support from drug manufacturers to enrollees for specific prescription drugs toward the annual limit on patient cost sharing amounts.
A new study in JCO Oncology Practice (JCO OP) shows that using clinical pathways in an oncology-specific alternative payment model (APM) can help reduce the cost of cancer care.
The Association for Clinical Oncology (ASCO) recently held a briefing on Capitol Hill to inform policymakers and other stakeholders about the need for the bipartisan CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs for Medicaid enrollees with life-threatening conditions participating in clinical trials.
The American Society of Clinical Oncology (ASCO) has developed a summary of updates from states and private payers in response to COVID-19. The summary includes information on coverage for laboratory tests, provider visits, telehealth, and other related care, along with changes to prior authorization requirements, network restrictions, and prescription refills, among other updates.
On March 6, 2020, President Trump signed into law the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. On January 31, 2020, Health and Human Services (HHS) Secretary Azar declared a public health emergency effective January 27, 2020, affording the Centers for Medicare & Medicaid Services (CMS) the flexibility to quickly support Medicare beneficiaries.
The American Society of Clinical Oncology’s (ASCO) latest policy brief on price transparency provides an overview of the issues complicating health care price transparency, the society’s concerns about how the lack of price transparency in the health care system is impacting people with cancer, and how drug manufacturers, pharmacy benefit managers, and other stakeholders can be more transparent in a way that is meaningful for patients and providers.